NCT03461783 is a NA clinical trial of Zorflex Activated Carbon Dressing in Wound Infection, sponsored by Brock Liden, DPM.

Who is sponsoring NCT03461783?

NCT03461783 is sponsored by Brock Liden, DPM.

What drugs are being tested in NCT03461783?

Interventions in NCT03461783: Zorflex Activated Carbon Dressing, Standard of Care.

What condition does NCT03461783 study?

NCT03461783 studies Wound Infection.

Is NCT03461783 still recruiting?

NCT03461783 is currently completed. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT03461783

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

Completed NA Last updated 27 February 2019

What this trial tests

NA trial testing Zorflex Activated Carbon Dressing in Wound Infection in 21 participants. Completed in 1 February 2019.

Timeline

26 June 2017

Primary endpoint
3 August 2018

1 February 2019

Quick facts

Lead sponsor	Brock Liden, DPM
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	26 June 2017
Primary completion	3 August 2018
Estimated completion	1 February 2019
Sites	2 locations across United States

Drugs / interventions tested

Zorflex Activated Carbon Dressing
Standard of Care

Conditions studied

Wound Infection — all drugs for Wound Infection →

Sponsor

Brock Liden, DPM

Who can join

18 and older, any sex, with Wound Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this randomized, prospective study is to evaluate how this activated carbon dressing affects the total bacterial load and biofilm in a wound bed in wounds of the lower extremity and foot. We anticipate that the use of Zorflex® Activated Carbon Cloth dressing will maintain the bacterial burden in the wound bed below the level of critical colonization, with potential secondary benefits of pain reduction, decrease in inflammation, and control of odor. Wound bed healing progression/acceleration also will be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Wound Infection

Currently open trials in the same condition.

NCT07501897 — Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Followin · NA · recruiting
NCT06841237 — Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management · NA · recruiting
NCT06576154 — The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias · Phase 3 · recruiting
NCT06025253 — PINTA - Prophylactic Incisional Negative Pressure Therapy for Major Amputations · NA · recruiting
NCT06220058 — Comparing Polypropylene Mesh and "Small Bites" Technique in Emergency Colorectal Surgery's Midline Laparotomy Closure. S · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03461783 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brock Liden, DPM
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03461783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing